Alpha 2.0
Login Register
» Articles » PMID: 17077361

Re: Response of a KIT-positive Extra-abdominal Fibromatosis to Imatinib Mesylate and KIT Genetic Analysis

Overview
Journal J Natl Cancer Inst
Publisher Oxford University Press
Specialty Oncology
Date 2006 Nov 2
PMID 17077361
Citations 5
Authors
Elena Tamborini
Tiziana Negri
Francesca Miselli
M Stefania Lagonigro
Sabrina Pricl
Silvana Pilotti
Affiliations
Soon will be listed here.
Citing Articles

Molecular and functional characterization of a new 3' end KIT juxtamembrane deletion in a duodenal GIST treated with neoadjuvant Imatinib.

Perfetti V, Laurini E, Aulic S, Fermeglia M, Riboni R, Lucioni M Oncotarget. 2017; 8(34):56158-56167.

PMID: 28915580 PMC: 5593551. DOI: 10.18632/oncotarget.19341.

AKT1 and BRAF mutations in pediatric aggressive fibromatosis.

Meazza C, Belfiore A, Busico A, Settanni G, Paielli N, Cesana L Cancer Med. 2016; 5(6):1204-13.

PMID: 27062580 PMC: 4924379. DOI: 10.1002/cam4.669.

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis.

Dufresne A, Bertucci F, Penel N, Le Cesne A, Bui B, Tubiana-Hulin M Br J Cancer. 2010; 103(4):482-5.

PMID: 20664593 PMC: 2939782. DOI: 10.1038/sj.bjc.6605783.

A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis.

Kurtz J, Asmane I, Voegeli A, Neuville A, Dufresne A, Litique V Sarcoma. 2010; 2010:458156.

PMID: 20339585 PMC: 2841250. DOI: 10.1155/2010/458156.

Targeted therapies: the rare cancer paradigm.

Pierotti M, Negri T, Tamborini E, Perrone F, Pricl S, Pilotti S Mol Oncol. 2009; 4(1):19-37.

PMID: 19913465 PMC: 5527958. DOI: 10.1016/j.molonc.2009.10.003.